| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 44 | 2023 | 926 | 4.580 |
Why?
|
| Hypersensitivity | 21 | 2023 | 231 | 3.680 |
Why?
|
| Mycoses | 12 | 2025 | 110 | 3.630 |
Why?
|
| Peptide Hydrolases | 12 | 2019 | 131 | 3.030 |
Why?
|
| Th2 Cells | 33 | 2021 | 186 | 2.710 |
Why?
|
| Lung | 44 | 2025 | 1566 | 2.460 |
Why?
|
| Th17 Cells | 11 | 2024 | 95 | 2.450 |
Why?
|
| Emphysema | 11 | 2022 | 67 | 2.380 |
Why?
|
| Fungal Proteins | 7 | 2025 | 132 | 2.320 |
Why?
|
| Respiratory Hypersensitivity | 11 | 2019 | 55 | 2.210 |
Why?
|
| Allergens | 18 | 2018 | 356 | 2.150 |
Why?
|
| Immunity, Innate | 18 | 2020 | 411 | 2.070 |
Why?
|
| Sinusitis | 10 | 2025 | 116 | 2.040 |
Why?
|
| Candida albicans | 4 | 2025 | 88 | 1.900 |
Why?
|
| Pulmonary Emphysema | 9 | 2025 | 95 | 1.860 |
Why?
|
| Fibrinogen | 5 | 2019 | 166 | 1.620 |
Why?
|
| Toll-Like Receptor 4 | 6 | 2023 | 140 | 1.600 |
Why?
|
| Candidiasis | 3 | 2025 | 132 | 1.580 |
Why?
|
| Interleukin-13 | 18 | 2018 | 96 | 1.420 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 12 | 2025 | 650 | 1.410 |
Why?
|
| CD11b Antigen | 2 | 2023 | 35 | 1.410 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 5 | 2021 | 17 | 1.380 |
Why?
|
| Fungi | 6 | 2023 | 73 | 1.380 |
Why?
|
| Antifungal Agents | 4 | 2025 | 298 | 1.370 |
Why?
|
| Animals | 109 | 2025 | 34404 | 1.360 |
Why?
|
| Viral Vaccines | 4 | 2020 | 317 | 1.300 |
Why?
|
| Mice | 87 | 2025 | 18482 | 1.290 |
Why?
|
| Aspergillus niger | 6 | 2021 | 16 | 1.260 |
Why?
|
| Cytokines | 23 | 2020 | 1348 | 1.230 |
Why?
|
| Respiratory Mucosa | 10 | 2020 | 96 | 1.190 |
Why?
|
| Lung Diseases, Fungal | 2 | 2019 | 37 | 1.140 |
Why?
|
| Inflammation | 17 | 2023 | 1493 | 1.120 |
Why?
|
| Respiratory System | 9 | 2026 | 97 | 1.100 |
Why?
|
| Rhinitis | 6 | 2024 | 41 | 1.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 6 | 2021 | 75 | 1.090 |
Why?
|
| Betacoronavirus | 3 | 2020 | 287 | 1.040 |
Why?
|
| Mice, Inbred C57BL | 47 | 2025 | 4768 | 1.030 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 366 | 1.030 |
Why?
|
| Disease Models, Animal | 35 | 2025 | 4685 | 1.020 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 378 | 1.000 |
Why?
|
| Th1 Cells | 7 | 2012 | 156 | 0.990 |
Why?
|
| Bronchial Hyperreactivity | 10 | 2021 | 34 | 0.980 |
Why?
|
| Cigarette Smoking | 5 | 2025 | 95 | 0.970 |
Why?
|
| Lung Diseases | 6 | 2018 | 401 | 0.930 |
Why?
|
| Immunity, Cellular | 8 | 2020 | 200 | 0.930 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2025 | 496 | 0.920 |
Why?
|
| Bronchoalveolar Lavage Fluid | 17 | 2018 | 155 | 0.900 |
Why?
|
| MicroRNAs | 5 | 2024 | 895 | 0.890 |
Why?
|
| STAT6 Transcription Factor | 8 | 2022 | 32 | 0.890 |
Why?
|
| Immunity | 5 | 2021 | 179 | 0.880 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2021 | 199 | 0.860 |
Why?
|
| Microglia | 2 | 2023 | 138 | 0.860 |
Why?
|
| Disease Susceptibility | 3 | 2021 | 283 | 0.820 |
Why?
|
| Aspergillus | 6 | 2022 | 26 | 0.790 |
Why?
|
| Candidemia | 2 | 2025 | 45 | 0.790 |
Why?
|
| Interleukin-4 | 21 | 2018 | 145 | 0.790 |
Why?
|
| Gastrointestinal Tract | 1 | 2025 | 225 | 0.790 |
Why?
|
| Mice, Knockout | 29 | 2019 | 3864 | 0.780 |
Why?
|
| Pandemics | 3 | 2020 | 1165 | 0.780 |
Why?
|
| Blood Platelets | 2 | 2025 | 316 | 0.770 |
Why?
|
| Humans | 108 | 2026 | 131759 | 0.690 |
Why?
|
| Lung Diseases, Parasitic | 2 | 2020 | 13 | 0.670 |
Why?
|
| Orthomyxoviridae Infections | 3 | 2025 | 58 | 0.670 |
Why?
|
| Helminthiasis | 2 | 2020 | 83 | 0.650 |
Why?
|
| Host-Parasite Interactions | 1 | 2020 | 72 | 0.650 |
Why?
|
| Leishmaniasis, Cutaneous | 6 | 2013 | 49 | 0.640 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 39 | 0.640 |
Why?
|
| DNA Cleavage | 2 | 2017 | 10 | 0.630 |
Why?
|
| Helminths | 1 | 2020 | 51 | 0.630 |
Why?
|
| Smoking | 12 | 2019 | 926 | 0.630 |
Why?
|
| Leishmania major | 5 | 2013 | 27 | 0.620 |
Why?
|
| Mice, Inbred BALB C | 19 | 2018 | 1020 | 0.620 |
Why?
|
| Lymphocyte Activation | 12 | 2021 | 681 | 0.620 |
Why?
|
| Host-Pathogen Interactions | 2 | 2021 | 260 | 0.620 |
Why?
|
| Antigen-Presenting Cells | 6 | 2019 | 133 | 0.610 |
Why?
|
| Matrix Metalloproteinase 2 | 5 | 2011 | 88 | 0.600 |
Why?
|
| Cerebrum | 1 | 2019 | 34 | 0.580 |
Why?
|
| Pulmonary Aspergillosis | 2 | 2021 | 9 | 0.580 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2018 | 27 | 0.580 |
Why?
|
| Adaptive Immunity | 5 | 2022 | 99 | 0.570 |
Why?
|
| Aspergillus fumigatus | 8 | 2019 | 43 | 0.560 |
Why?
|
| Signal Transduction | 14 | 2024 | 4683 | 0.530 |
Why?
|
| Memory Disorders | 1 | 2019 | 207 | 0.510 |
Why?
|
| Dendritic Cells | 10 | 2022 | 437 | 0.510 |
Why?
|
| Cell Differentiation | 13 | 2024 | 1948 | 0.500 |
Why?
|
| T-Lymphocytes | 12 | 2017 | 1790 | 0.500 |
Why?
|
| Bronchodilator Agents | 1 | 2018 | 153 | 0.500 |
Why?
|
| Airway Obstruction | 5 | 2011 | 177 | 0.490 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2020 | 385 | 0.490 |
Why?
|
| Respiratory Tract Infections | 1 | 2019 | 293 | 0.490 |
Why?
|
| Dust | 3 | 2011 | 31 | 0.480 |
Why?
|
| Autoimmunity | 6 | 2019 | 182 | 0.480 |
Why?
|
| Sputum | 2 | 2018 | 118 | 0.480 |
Why?
|
| Exercise Test | 3 | 2015 | 243 | 0.480 |
Why?
|
| CD11a Antigen | 2 | 2013 | 11 | 0.470 |
Why?
|
| Peptidomimetics | 1 | 2015 | 12 | 0.470 |
Why?
|
| Interleukin-17 | 7 | 2024 | 128 | 0.470 |
Why?
|
| Biomarkers | 7 | 2025 | 3407 | 0.460 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2015 | 51 | 0.460 |
Why?
|
| Influenza Vaccines | 4 | 2020 | 500 | 0.450 |
Why?
|
| Matrix Metalloproteinase 9 | 5 | 2019 | 139 | 0.450 |
Why?
|
| Gene Expression Regulation | 8 | 2020 | 2353 | 0.430 |
Why?
|
| Soot | 3 | 2022 | 14 | 0.430 |
Why?
|
| Bronchitis | 2 | 2012 | 33 | 0.420 |
Why?
|
| Nasal Polyps | 5 | 2025 | 28 | 0.420 |
Why?
|
| Eosinophils | 6 | 2021 | 126 | 0.420 |
Why?
|
| Aspergillus oryzae | 3 | 2013 | 8 | 0.420 |
Why?
|
| CD18 Antigens | 2 | 2004 | 44 | 0.420 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 133 | 0.410 |
Why?
|
| Immunity, Mucosal | 2 | 2011 | 90 | 0.410 |
Why?
|
| Inflammation Mediators | 3 | 2020 | 228 | 0.400 |
Why?
|
| Interleukin-5 | 7 | 2018 | 51 | 0.390 |
Why?
|
| Lung Neoplasms | 5 | 2025 | 1542 | 0.390 |
Why?
|
| Status Asthmaticus | 2 | 2012 | 22 | 0.390 |
Why?
|
| Tracheitis | 1 | 2012 | 14 | 0.390 |
Why?
|
| Argonaute Proteins | 1 | 2012 | 29 | 0.390 |
Why?
|
| RNA, Antisense | 1 | 2012 | 35 | 0.390 |
Why?
|
| Mycosis Fungoides | 1 | 2012 | 14 | 0.390 |
Why?
|
| Interleukins | 5 | 2024 | 121 | 0.380 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2012 | 36 | 0.380 |
Why?
|
| Flow Cytometry | 6 | 2014 | 769 | 0.380 |
Why?
|
| Influenza, Human | 4 | 2025 | 703 | 0.380 |
Why?
|
| Interferon-gamma | 15 | 2019 | 542 | 0.380 |
Why?
|
| Severity of Illness Index | 8 | 2025 | 3093 | 0.380 |
Why?
|
| Bronchoalveolar Lavage | 2 | 2010 | 22 | 0.380 |
Why?
|
| Epithelial Cells | 6 | 2021 | 900 | 0.380 |
Why?
|
| Chemokines, CC | 4 | 2005 | 26 | 0.370 |
Why?
|
| Pneumonia | 4 | 2011 | 344 | 0.370 |
Why?
|
| Cell Movement | 6 | 2018 | 886 | 0.370 |
Why?
|
| Elastin | 3 | 2019 | 32 | 0.360 |
Why?
|
| B-Lymphocytes | 7 | 2024 | 529 | 0.360 |
Why?
|
| Female | 47 | 2026 | 71214 | 0.360 |
Why?
|
| CD28 Antigens | 2 | 2006 | 75 | 0.360 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2012 | 34 | 0.360 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 875 | 0.360 |
Why?
|
| Nanoparticles | 2 | 2015 | 292 | 0.350 |
Why?
|
| Spores, Fungal | 3 | 2021 | 14 | 0.350 |
Why?
|
| Bacteremia | 2 | 2025 | 428 | 0.350 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2012 | 132 | 0.340 |
Why?
|
| Interleukin-10 | 6 | 2019 | 185 | 0.340 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2019 | 643 | 0.340 |
Why?
|
| Repressor Proteins | 1 | 2015 | 781 | 0.340 |
Why?
|
| Immunoglobulin E | 6 | 2014 | 225 | 0.340 |
Why?
|
| Bronchi | 4 | 2021 | 102 | 0.330 |
Why?
|
| HIV | 1 | 2012 | 179 | 0.330 |
Why?
|
| Influenza A virus | 2 | 2025 | 149 | 0.330 |
Why?
|
| Adjuvants, Immunologic | 4 | 2020 | 393 | 0.330 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2025 | 327 | 0.330 |
Why?
|
| Specific Pathogen-Free Organisms | 2 | 2025 | 58 | 0.320 |
Why?
|
| Dermatitis, Atopic | 1 | 2011 | 54 | 0.320 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 1 | 2012 | 281 | 0.320 |
Why?
|
| Ovalbumin | 11 | 2018 | 119 | 0.310 |
Why?
|
| Amyloid beta-Peptides | 2 | 2023 | 236 | 0.310 |
Why?
|
| Respiratory Function Tests | 3 | 2011 | 225 | 0.310 |
Why?
|
| Smoke | 5 | 2025 | 81 | 0.290 |
Why?
|
| Cells, Cultured | 13 | 2019 | 2969 | 0.290 |
Why?
|
| Chronic Disease | 7 | 2025 | 1235 | 0.290 |
Why?
|
| Pulmonary Alveoli | 1 | 2009 | 139 | 0.280 |
Why?
|
| Macrophages, Alveolar | 5 | 2025 | 50 | 0.280 |
Why?
|
| Rhinitis, Allergic | 2 | 2025 | 19 | 0.280 |
Why?
|
| Antigens, Fungal | 7 | 2014 | 34 | 0.270 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2008 | 31 | 0.270 |
Why?
|
| Integrins | 1 | 2008 | 90 | 0.270 |
Why?
|
| NF-kappa B | 3 | 2019 | 449 | 0.270 |
Why?
|
| Cell Separation | 2 | 2011 | 222 | 0.260 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2019 | 234 | 0.260 |
Why?
|
| Aged | 18 | 2026 | 21259 | 0.260 |
Why?
|
| Down-Regulation | 3 | 2024 | 659 | 0.260 |
Why?
|
| Leukopenia | 1 | 2006 | 45 | 0.250 |
Why?
|
| Chemotaxis | 2 | 2003 | 62 | 0.250 |
Why?
|
| Middle Aged | 22 | 2026 | 28892 | 0.250 |
Why?
|
| Adult | 19 | 2026 | 31700 | 0.250 |
Why?
|
| Interleukin-1 | 2 | 2017 | 131 | 0.240 |
Why?
|
| Azithromycin | 1 | 2026 | 45 | 0.240 |
Why?
|
| Male | 31 | 2026 | 65274 | 0.240 |
Why?
|
| Receptors, CXCR6 | 1 | 2025 | 10 | 0.240 |
Why?
|
| Inhalation Exposure | 2 | 2021 | 38 | 0.230 |
Why?
|
| Receptors, Prostaglandin E | 1 | 2005 | 7 | 0.230 |
Why?
|
| Clinical Trials as Topic | 3 | 2020 | 1139 | 0.230 |
Why?
|
| Receptors, Immunologic | 1 | 2006 | 126 | 0.230 |
Why?
|
| Neovascularization, Physiologic | 2 | 2017 | 204 | 0.230 |
Why?
|
| Receptors, IgG | 1 | 2025 | 59 | 0.220 |
Why?
|
| Software | 2 | 2007 | 752 | 0.220 |
Why?
|
| Proteoglycans | 1 | 2005 | 79 | 0.220 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2025 | 105 | 0.220 |
Why?
|
| Receptors, Complement | 3 | 2014 | 31 | 0.220 |
Why?
|
| Mucus | 3 | 2018 | 38 | 0.220 |
Why?
|
| Mathematical Computing | 1 | 2004 | 9 | 0.220 |
Why?
|
| Neuraminidase | 1 | 2025 | 40 | 0.220 |
Why?
|
| Plasma Cells | 1 | 2025 | 55 | 0.220 |
Why?
|
| Symbiosis | 1 | 2025 | 94 | 0.220 |
Why?
|
| Acute Lung Injury | 1 | 2025 | 67 | 0.220 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2025 | 115 | 0.220 |
Why?
|
| Proteomics | 2 | 2009 | 609 | 0.220 |
Why?
|
| Immunologic Factors | 1 | 2006 | 192 | 0.210 |
Why?
|
| Bronchoconstriction | 3 | 2021 | 14 | 0.210 |
Why?
|
| Job Syndrome | 1 | 2024 | 18 | 0.210 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2024 | 10 | 0.210 |
Why?
|
| Immune Tolerance | 5 | 2019 | 159 | 0.210 |
Why?
|
| Antigens, Neoplasm | 2 | 2025 | 405 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 1010 | 0.200 |
Why?
|
| Body Fluids | 1 | 2024 | 46 | 0.200 |
Why?
|
| Thrombocytopenia | 1 | 2025 | 222 | 0.200 |
Why?
|
| Data Interpretation, Statistical | 1 | 2004 | 227 | 0.200 |
Why?
|
| Respiratory Insufficiency | 1 | 2025 | 242 | 0.190 |
Why?
|
| Goblet Cells | 3 | 2015 | 104 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2025 | 694 | 0.190 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 421 | 0.190 |
Why?
|
| Antibodies, Viral | 5 | 2020 | 1173 | 0.190 |
Why?
|
| Immunologic Memory | 3 | 2014 | 202 | 0.190 |
Why?
|
| Heart Diseases | 1 | 2007 | 505 | 0.190 |
Why?
|
| Neutrophils | 3 | 2019 | 372 | 0.190 |
Why?
|
| Immune System Diseases | 1 | 2003 | 52 | 0.190 |
Why?
|
| RNA, Messenger | 8 | 2015 | 2569 | 0.190 |
Why?
|
| Interleukin-6 | 2 | 2024 | 419 | 0.180 |
Why?
|
| STAT3 Transcription Factor | 1 | 2024 | 233 | 0.180 |
Why?
|
| Respiration, Artificial | 1 | 2025 | 501 | 0.180 |
Why?
|
| Endopeptidases | 1 | 2002 | 108 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2004 | 158 | 0.180 |
Why?
|
| Endothelial Cells | 1 | 2025 | 536 | 0.180 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 2021 | 4 | 0.180 |
Why?
|
| Intensive Care Units | 1 | 2025 | 517 | 0.180 |
Why?
|
| Protein Binding | 3 | 2019 | 1712 | 0.180 |
Why?
|
| Serine Endopeptidases | 1 | 2002 | 199 | 0.180 |
Why?
|
| Tobacco Products | 2 | 2019 | 61 | 0.180 |
Why?
|
| Glycoproteins | 1 | 2004 | 349 | 0.180 |
Why?
|
| Interleukin-33 | 2 | 2019 | 21 | 0.180 |
Why?
|
| Arachis | 1 | 2022 | 77 | 0.180 |
Why?
|
| Computers | 1 | 2021 | 70 | 0.180 |
Why?
|
| Interleukin-1beta | 2 | 2019 | 159 | 0.170 |
Why?
|
| Research Design | 1 | 2006 | 723 | 0.170 |
Why?
|
| Conjunctiva | 2 | 2015 | 197 | 0.170 |
Why?
|
| Complement C3a | 4 | 2015 | 18 | 0.170 |
Why?
|
| Peptide Fragments | 3 | 2019 | 781 | 0.170 |
Why?
|
| Lymphocytes | 2 | 2020 | 359 | 0.170 |
Why?
|
| Antibodies, Neutralizing | 3 | 2020 | 520 | 0.170 |
Why?
|
| Sepsis | 1 | 2025 | 501 | 0.170 |
Why?
|
| Life Cycle Stages | 1 | 2020 | 25 | 0.170 |
Why?
|
| Chemokines | 2 | 2014 | 127 | 0.170 |
Why?
|
| Peanut Hypersensitivity | 1 | 2022 | 89 | 0.170 |
Why?
|
| Air Pollutants | 1 | 2002 | 126 | 0.170 |
Why?
|
| Eosinophilia | 1 | 2022 | 109 | 0.170 |
Why?
|
| Neoplasm Proteins | 1 | 2025 | 677 | 0.170 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 665 | 0.160 |
Why?
|
| Microbiota | 1 | 2026 | 441 | 0.160 |
Why?
|
| Disease Outbreaks | 1 | 2002 | 314 | 0.160 |
Why?
|
| Immunomodulation | 1 | 2020 | 80 | 0.160 |
Why?
|
| Influenza A Virus, H7N7 Subtype | 1 | 2020 | 11 | 0.160 |
Why?
|
| Transcription Factor AP-1 | 2 | 2015 | 112 | 0.160 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2015 | 358 | 0.160 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2020 | 22 | 0.160 |
Why?
|
| Models, Theoretical | 1 | 2022 | 366 | 0.160 |
Why?
|
| Influenza in Birds | 1 | 2020 | 27 | 0.160 |
Why?
|
| Critical Care | 1 | 2025 | 680 | 0.160 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 302 | 0.160 |
Why?
|
| Influenza A Virus, H7N9 Subtype | 1 | 2020 | 29 | 0.160 |
Why?
|
| Antibodies, Fungal | 2 | 2014 | 13 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2020 | 400 | 0.160 |
Why?
|
| src Homology Domains | 2 | 2018 | 35 | 0.150 |
Why?
|
| HIV Infections | 1 | 2012 | 2037 | 0.150 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2020 | 153 | 0.150 |
Why?
|
| Complement C1q | 1 | 2019 | 18 | 0.150 |
Why?
|
| Macrophages | 4 | 2022 | 665 | 0.150 |
Why?
|
| Sarcoidosis | 1 | 2019 | 52 | 0.150 |
Why?
|
| Drug Design | 1 | 2020 | 166 | 0.150 |
Why?
|
| Retrospective Studies | 5 | 2025 | 17662 | 0.150 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2017 | 105 | 0.140 |
Why?
|
| Killer Cells, Natural | 3 | 2025 | 344 | 0.140 |
Why?
|
| Disease Progression | 7 | 2024 | 2221 | 0.140 |
Why?
|
| Protein Subunits | 1 | 2019 | 163 | 0.140 |
Why?
|
| Cell Adhesion | 2 | 2013 | 312 | 0.140 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2019 | 59 | 0.140 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2018 | 18 | 0.140 |
Why?
|
| Cognitive Dysfunction | 1 | 2023 | 355 | 0.140 |
Why?
|
| Monocytes | 1 | 2020 | 337 | 0.140 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2019 | 114 | 0.140 |
Why?
|
| Protein Domains | 1 | 2019 | 249 | 0.140 |
Why?
|
| Plethysmography | 1 | 2018 | 34 | 0.140 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 222 | 0.140 |
Why?
|
| Ascariasis | 1 | 2018 | 76 | 0.140 |
Why?
|
| STAT5 Transcription Factor | 1 | 2018 | 86 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 31 | 0.140 |
Why?
|
| Leukocyte Count | 1 | 2018 | 248 | 0.130 |
Why?
|
| Bronchial Provocation Tests | 2 | 2010 | 13 | 0.130 |
Why?
|
| Adoptive Transfer | 4 | 2019 | 236 | 0.130 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2025 | 835 | 0.130 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2018 | 158 | 0.130 |
Why?
|
| Cell Line | 5 | 2019 | 2606 | 0.130 |
Why?
|
| Small Molecule Libraries | 1 | 2018 | 135 | 0.130 |
Why?
|
| Coccidioidomycosis | 1 | 1996 | 9 | 0.120 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2019 | 300 | 0.120 |
Why?
|
| Polymorphism, Genetic | 2 | 2025 | 794 | 0.120 |
Why?
|
| Cystic Fibrosis | 1 | 2019 | 267 | 0.120 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 371 | 0.120 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1998 | 210 | 0.120 |
Why?
|
| Salmeterol Xinafoate | 1 | 2015 | 12 | 0.120 |
Why?
|
| Peripheral Tolerance | 1 | 2015 | 3 | 0.120 |
Why?
|
| Arrestins | 1 | 2015 | 25 | 0.120 |
Why?
|
| Autoantibodies | 1 | 2019 | 466 | 0.120 |
Why?
|
| beta-Arrestins | 1 | 2015 | 31 | 0.120 |
Why?
|
| Propanolamines | 1 | 2015 | 18 | 0.120 |
Why?
|
| Phosphopeptides | 1 | 2015 | 25 | 0.120 |
Why?
|
| Formoterol Fumarate | 1 | 2015 | 29 | 0.120 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2015 | 20 | 0.120 |
Why?
|
| Carbazoles | 1 | 2015 | 30 | 0.120 |
Why?
|
| Retinal Neovascularization | 1 | 2015 | 12 | 0.120 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 57 | 0.120 |
Why?
|
| Albuterol | 1 | 2015 | 53 | 0.120 |
Why?
|
| Astrocytes | 1 | 2019 | 288 | 0.120 |
Why?
|
| Homeostasis | 3 | 2019 | 714 | 0.120 |
Why?
|
| Mucin 5AC | 1 | 2015 | 21 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 388 | 0.120 |
Why?
|
| Cross-Priming | 1 | 2015 | 5 | 0.120 |
Why?
|
| Silicon | 1 | 2015 | 13 | 0.120 |
Why?
|
| Osteopontin | 2 | 2014 | 51 | 0.110 |
Why?
|
| Chemokine CCL11 | 3 | 2005 | 12 | 0.110 |
Why?
|
| Microspheres | 1 | 2015 | 68 | 0.110 |
Why?
|
| Respiratory Mechanics | 2 | 2007 | 80 | 0.110 |
Why?
|
| Immunization, Secondary | 1 | 2015 | 119 | 0.110 |
Why?
|
| Retinopathy of Prematurity | 1 | 2015 | 64 | 0.110 |
Why?
|
| B7-1 Antigen | 1 | 1994 | 12 | 0.110 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 119 | 0.110 |
Why?
|
| Environmental Exposure | 1 | 2018 | 291 | 0.110 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 2 | 2015 | 48 | 0.110 |
Why?
|
| Intestines | 1 | 2019 | 592 | 0.110 |
Why?
|
| Leukotrienes | 1 | 2014 | 7 | 0.110 |
Why?
|
| Interferon Type I | 1 | 2015 | 115 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 463 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2019 | 3451 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 1994 | 49 | 0.110 |
Why?
|
| Leishmaniasis | 1 | 1994 | 40 | 0.110 |
Why?
|
| Immunophenotyping | 3 | 2025 | 336 | 0.110 |
Why?
|
| RNA | 3 | 2013 | 531 | 0.110 |
Why?
|
| Molecular Sequence Data | 8 | 2008 | 3616 | 0.110 |
Why?
|
| Homeodomain Proteins | 3 | 2011 | 568 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2026 | 2576 | 0.100 |
Why?
|
| Kv1.3 Potassium Channel | 1 | 2014 | 38 | 0.100 |
Why?
|
| Dose-Response Relationship, Immunologic | 2 | 2011 | 106 | 0.100 |
Why?
|
| PPAR gamma | 1 | 2014 | 86 | 0.100 |
Why?
|
| Th1-Th2 Balance | 1 | 2013 | 8 | 0.100 |
Why?
|
| Thiazolidinediones | 1 | 2014 | 79 | 0.100 |
Why?
|
| Virus Replication | 2 | 2021 | 597 | 0.100 |
Why?
|
| Chemokine CCL7 | 2 | 2004 | 7 | 0.100 |
Why?
|
| Chemokine CCL17 | 2 | 2004 | 11 | 0.100 |
Why?
|
| Monocyte Chemoattractant Proteins | 2 | 2004 | 7 | 0.100 |
Why?
|
| Pulmonary Eosinophilia | 2 | 2011 | 8 | 0.100 |
Why?
|
| Macrophage Activation | 1 | 2013 | 64 | 0.100 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2013 | 25 | 0.100 |
Why?
|
| STAT Transcription Factors | 1 | 2013 | 25 | 0.100 |
Why?
|
| Tuberculosis | 1 | 2019 | 552 | 0.100 |
Why?
|
| Gene Expression | 3 | 2015 | 1502 | 0.100 |
Why?
|
| Tyrosine | 2 | 2015 | 148 | 0.100 |
Why?
|
| RNA Precursors | 1 | 2012 | 42 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2004 | 792 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 233 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 759 | 0.090 |
Why?
|
| Neoplasms | 2 | 2019 | 2966 | 0.090 |
Why?
|
| Phenotype | 5 | 2024 | 4528 | 0.090 |
Why?
|
| Ligands | 1 | 2013 | 486 | 0.090 |
Why?
|
| Tumor Microenvironment | 3 | 2023 | 704 | 0.090 |
Why?
|
| Chitin | 1 | 2011 | 6 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2006 | 580 | 0.090 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2009 | 41 | 0.090 |
Why?
|
| Gene Deletion | 2 | 2005 | 773 | 0.090 |
Why?
|
| Cell Proliferation | 5 | 2019 | 2483 | 0.090 |
Why?
|
| Nasal Mucosa | 2 | 2024 | 83 | 0.090 |
Why?
|
| Dry Eye Syndromes | 1 | 2015 | 294 | 0.090 |
Why?
|
| Calgranulin B | 2 | 2008 | 8 | 0.090 |
Why?
|
| beta-N-Acetylhexosaminidases | 2 | 2008 | 9 | 0.090 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2019 | 699 | 0.080 |
Why?
|
| Lectins | 2 | 2008 | 50 | 0.080 |
Why?
|
| Forecasting | 2 | 2005 | 361 | 0.080 |
Why?
|
| Gene Duplication | 1 | 2012 | 364 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 998 | 0.080 |
Why?
|
| Mice, Inbred CBA | 1 | 2010 | 27 | 0.080 |
Why?
|
| Autophagy | 1 | 2014 | 424 | 0.080 |
Why?
|
| Alleles | 2 | 2025 | 1711 | 0.080 |
Why?
|
| Vaccines, Subunit | 1 | 2010 | 72 | 0.080 |
Why?
|
| Rhinovirus | 1 | 2010 | 65 | 0.080 |
Why?
|
| Picornaviridae Infections | 1 | 2010 | 50 | 0.080 |
Why?
|
| Cysteine Endopeptidases | 1 | 2010 | 113 | 0.080 |
Why?
|
| Leishmania braziliensis | 1 | 2009 | 1 | 0.080 |
Why?
|
| Transcription, Genetic | 2 | 2021 | 1398 | 0.080 |
Why?
|
| DNA, Complementary | 3 | 1994 | 436 | 0.080 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2009 | 25 | 0.070 |
Why?
|
| Dermatitis | 1 | 2009 | 29 | 0.070 |
Why?
|
| Cell Migration Inhibition | 2 | 2006 | 11 | 0.070 |
Why?
|
| Exercise | 2 | 2007 | 866 | 0.070 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2009 | 55 | 0.070 |
Why?
|
| Airway Resistance | 2 | 2006 | 32 | 0.070 |
Why?
|
| Peritonitis | 1 | 2009 | 75 | 0.070 |
Why?
|
| Tretinoin | 1 | 2009 | 97 | 0.070 |
Why?
|
| Pneumococcal Infections | 1 | 2011 | 279 | 0.070 |
Why?
|
| Complement C3 | 2 | 2014 | 43 | 0.070 |
Why?
|
| Brain Diseases | 1 | 2011 | 305 | 0.070 |
Why?
|
| RNA Editing | 1 | 2008 | 32 | 0.070 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2008 | 14 | 0.070 |
Why?
|
| Receptors, Interleukin | 3 | 2006 | 37 | 0.070 |
Why?
|
| Streptococcus pneumoniae | 1 | 2011 | 389 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 4 | 1996 | 1489 | 0.070 |
Why?
|
| Viral Proteins | 1 | 2010 | 339 | 0.070 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2009 | 98 | 0.070 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2008 | 29 | 0.070 |
Why?
|
| Integrin beta1 | 1 | 2008 | 54 | 0.070 |
Why?
|
| Subtraction Technique | 1 | 2008 | 36 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2015 | 1018 | 0.070 |
Why?
|
| Anaerobic Threshold | 1 | 2007 | 11 | 0.070 |
Why?
|
| Pulmonary Gas Exchange | 1 | 2007 | 34 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2008 | 62 | 0.070 |
Why?
|
| Antibodies, Anti-Idiotypic | 2 | 2006 | 42 | 0.070 |
Why?
|
| Vaccines, Inactivated | 2 | 2020 | 149 | 0.070 |
Why?
|
| Receptors, Interleukin-4 | 4 | 2015 | 11 | 0.070 |
Why?
|
| Leukocyte Elastase | 2 | 2019 | 20 | 0.070 |
Why?
|
| Matrix Metalloproteinase 12 | 2 | 2019 | 14 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1518 | 0.070 |
Why?
|
| Transcriptome | 3 | 2021 | 1148 | 0.060 |
Why?
|
| Polystyrenes | 1 | 2006 | 8 | 0.060 |
Why?
|
| Mice, Inbred Strains | 1 | 2007 | 297 | 0.060 |
Why?
|
| Membrane Proteins | 3 | 2006 | 1610 | 0.060 |
Why?
|
| Texas | 2 | 2025 | 3622 | 0.060 |
Why?
|
| Dipeptidases | 2 | 2006 | 15 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 301 | 0.060 |
Why?
|
| Fluorescence | 1 | 2006 | 97 | 0.060 |
Why?
|
| Leukotriene C4 | 1 | 2006 | 3 | 0.060 |
Why?
|
| Coculture Techniques | 2 | 2019 | 232 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2007 | 179 | 0.060 |
Why?
|
| Arylsulfonates | 1 | 2006 | 3 | 0.060 |
Why?
|
| Sulfonium Compounds | 1 | 2006 | 5 | 0.060 |
Why?
|
| Reference Values | 1 | 2007 | 692 | 0.060 |
Why?
|
| Animal Experimentation | 1 | 2006 | 3 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2026 | 6507 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2018 | 152 | 0.060 |
Why?
|
| Anti-Allergic Agents | 1 | 2006 | 29 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 356 | 0.060 |
Why?
|
| Omalizumab | 1 | 2006 | 39 | 0.060 |
Why?
|
| Structure-Activity Relationship | 2 | 2018 | 579 | 0.060 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 1 | 2005 | 1 | 0.060 |
Why?
|
| Syndecans | 1 | 2005 | 4 | 0.060 |
Why?
|
| Syndecan-1 | 1 | 2005 | 7 | 0.060 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2025 | 19 | 0.060 |
Why?
|
| Prognosis | 2 | 2015 | 4953 | 0.060 |
Why?
|
| Multiple Organ Failure | 1 | 2006 | 143 | 0.060 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 2005 | 20 | 0.060 |
Why?
|
| Shock, Septic | 1 | 2006 | 149 | 0.060 |
Why?
|
| Base Sequence | 6 | 2008 | 2783 | 0.060 |
Why?
|
| Platelet Count | 1 | 2025 | 140 | 0.060 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2025 | 7 | 0.060 |
Why?
|
| Dinoprostone | 1 | 2005 | 67 | 0.060 |
Why?
|
| Administration, Intranasal | 1 | 2005 | 130 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2007 | 531 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2010 | 765 | 0.060 |
Why?
|
| Enzyme Activation | 2 | 2003 | 590 | 0.060 |
Why?
|
| Acute Disease | 1 | 2008 | 1153 | 0.050 |
Why?
|
| Proteome | 1 | 2006 | 286 | 0.050 |
Why?
|
| Sensation Disorders | 1 | 2024 | 24 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 2565 | 0.050 |
Why?
|
| Antibodies | 1 | 2006 | 358 | 0.050 |
Why?
|
| Child | 4 | 2025 | 26307 | 0.050 |
Why?
|
| Heart Rate | 1 | 2007 | 580 | 0.050 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2024 | 38 | 0.050 |
Why?
|
| Mice, SCID | 2 | 1996 | 579 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2018 | 1610 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2026 | 303 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 723 | 0.050 |
Why?
|
| Viral Load | 1 | 2025 | 406 | 0.050 |
Why?
|
| Ambrosia | 1 | 2002 | 15 | 0.050 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2026 | 398 | 0.050 |
Why?
|
| Leukocytes | 1 | 2004 | 211 | 0.050 |
Why?
|
| Leukotriene D4 | 1 | 2002 | 5 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2003 | 189 | 0.050 |
Why?
|
| Immunoglobulin G | 2 | 2002 | 810 | 0.050 |
Why?
|
| Pollen | 1 | 2002 | 49 | 0.050 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 3836 | 0.050 |
Why?
|
| Obesity | 2 | 2005 | 2390 | 0.050 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2002 | 17 | 0.050 |
Why?
|
| Endothelium | 1 | 2002 | 63 | 0.050 |
Why?
|
| Carbon | 1 | 2022 | 94 | 0.050 |
Why?
|
| Troponin | 1 | 2022 | 70 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2002 | 132 | 0.050 |
Why?
|
| Phagocytosis | 2 | 2015 | 191 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2018 | 12993 | 0.050 |
Why?
|
| Risk Factors | 3 | 2025 | 10961 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2015 | 530 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 1835 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1626 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2022 | 92 | 0.050 |
Why?
|
| Bacteria | 1 | 2026 | 532 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 366 | 0.040 |
Why?
|
| Dipeptides | 1 | 2002 | 64 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 2002 | 101 | 0.040 |
Why?
|
| Brain | 2 | 2024 | 3235 | 0.040 |
Why?
|
| Machine Learning | 1 | 2025 | 375 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2002 | 95 | 0.040 |
Why?
|
| Metabolomics | 1 | 2025 | 493 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2014 | 2363 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2014 | 60 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2009 | 947 | 0.040 |
Why?
|
| Critical Illness | 1 | 2025 | 616 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2025 | 1457 | 0.040 |
Why?
|
| A549 Cells | 1 | 2021 | 49 | 0.040 |
Why?
|
| Immunoglobulin Isotypes | 2 | 2002 | 15 | 0.040 |
Why?
|
| Aspirin | 1 | 2002 | 216 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2015 | 1571 | 0.040 |
Why?
|
| Desensitization, Immunologic | 1 | 2022 | 118 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 402 | 0.040 |
Why?
|
| Alum Compounds | 1 | 2020 | 43 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2002 | 302 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2025 | 1076 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2022 | 512 | 0.040 |
Why?
|
| Receptors, IgE | 1 | 1999 | 11 | 0.040 |
Why?
|
| Proteins | 2 | 2014 | 1027 | 0.040 |
Why?
|
| Birds | 1 | 2020 | 87 | 0.040 |
Why?
|
| Solvents | 1 | 2019 | 44 | 0.040 |
Why?
|
| Recombinant Proteins | 3 | 2014 | 1316 | 0.040 |
Why?
|
| Receptor, PAR-2 | 1 | 2019 | 4 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 134 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2002 | 832 | 0.040 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 1999 | 41 | 0.040 |
Why?
|
| Paranasal Sinuses | 1 | 2019 | 18 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2025 | 6915 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2019 | 38 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 136 | 0.040 |
Why?
|
| Phospholipids | 1 | 2019 | 103 | 0.040 |
Why?
|
| Vital Capacity | 1 | 2019 | 88 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2019 | 107 | 0.040 |
Why?
|
| Smokers | 1 | 2019 | 44 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 146 | 0.040 |
Why?
|
| Ascaris | 1 | 2018 | 13 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2020 | 496 | 0.040 |
Why?
|
| Nicotine | 1 | 2019 | 117 | 0.040 |
Why?
|
| Rats | 2 | 2015 | 3460 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2019 | 176 | 0.040 |
Why?
|
| Chemokine CXCL10 | 2 | 2011 | 52 | 0.030 |
Why?
|
| Larva | 1 | 2018 | 252 | 0.030 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2017 | 5 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 382 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2018 | 58 | 0.030 |
Why?
|
| Genes, T-Cell Receptor delta | 1 | 2017 | 8 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2017 | 45 | 0.030 |
Why?
|
| Mucous Membrane | 2 | 2013 | 88 | 0.030 |
Why?
|
| Colitis | 1 | 2019 | 159 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2025 | 3692 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 140 | 0.030 |
Why?
|
| Apoptosis | 1 | 2004 | 1861 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1997 | 57 | 0.030 |
Why?
|
| Crosses, Genetic | 1 | 1997 | 155 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 105 | 0.030 |
Why?
|
| Aging | 1 | 2024 | 1266 | 0.030 |
Why?
|
| beta 2-Microglobulin | 1 | 1996 | 36 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 231 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 1997 | 79 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2019 | 810 | 0.030 |
Why?
|
| Pseudomonas Infections | 1 | 1997 | 117 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 254 | 0.030 |
Why?
|
| Antigens | 1 | 1996 | 149 | 0.030 |
Why?
|
| Hydrostatic Pressure | 1 | 1996 | 10 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2860 | 0.030 |
Why?
|
| Receptors, Interleukin-3 | 1 | 2015 | 4 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2025 | 5122 | 0.030 |
Why?
|
| Pulmonary Ventilation | 1 | 1996 | 30 | 0.030 |
Why?
|
| Granzymes | 1 | 2015 | 47 | 0.030 |
Why?
|
| Phagocytes | 1 | 2015 | 25 | 0.030 |
Why?
|
| Acetylcholine | 1 | 1996 | 82 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2015 | 85 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2018 | 598 | 0.030 |
Why?
|
| Prodrugs | 1 | 2015 | 56 | 0.030 |
Why?
|
| Porosity | 1 | 2015 | 43 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 713 | 0.030 |
Why?
|
| Trophoblasts | 1 | 1996 | 117 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 95 | 0.030 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2015 | 99 | 0.030 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2015 | 60 | 0.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 138 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 2014 | 28 | 0.030 |
Why?
|
| Abatacept | 1 | 1994 | 26 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2007 | 2082 | 0.030 |
Why?
|
| Complement Activation | 1 | 2014 | 47 | 0.030 |
Why?
|
| Antigens, Differentiation | 1 | 1994 | 63 | 0.030 |
Why?
|
| Vaccination | 1 | 2020 | 1044 | 0.030 |
Why?
|
| Paracrine Communication | 1 | 2014 | 68 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 1994 | 64 | 0.030 |
Why?
|
| Therapeutic Irrigation | 1 | 2014 | 44 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 1994 | 124 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 1322 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2014 | 99 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 414 | 0.030 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2015 | 135 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2025 | 3416 | 0.030 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2014 | 41 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2015 | 157 | 0.030 |
Why?
|
| RNA Interference | 1 | 2015 | 496 | 0.030 |
Why?
|
| Potassium Channel Blockers | 1 | 2014 | 84 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2015 | 955 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 960 | 0.030 |
Why?
|
| Proteolysis | 1 | 2014 | 195 | 0.030 |
Why?
|
| Bronchoconstrictor Agents | 2 | 2003 | 8 | 0.030 |
Why?
|
| Methacholine Chloride | 2 | 2003 | 16 | 0.030 |
Why?
|
| Cancer Vaccines | 1 | 2015 | 191 | 0.030 |
Why?
|
| Hospitalization | 1 | 2022 | 1942 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2013 | 84 | 0.020 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 2 | 2006 | 6 | 0.020 |
Why?
|
| Receptors, Interleukin-13 | 2 | 2006 | 4 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 854 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 482 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2013 | 291 | 0.020 |
Why?
|
| Immunization | 1 | 2014 | 307 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1994 | 418 | 0.020 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 188 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2015 | 517 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1087 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2015 | 1024 | 0.020 |
Why?
|
| Antigens, CD1 | 1 | 2012 | 23 | 0.020 |
Why?
|
| Chitinases | 1 | 2011 | 4 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 53 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 633 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2014 | 1008 | 0.020 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 47 | 0.020 |
Why?
|
| Young Adult | 2 | 2015 | 10099 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2010 | 130 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 2122 | 0.020 |
Why?
|
| Genomics | 1 | 2018 | 1626 | 0.020 |
Why?
|
| Retinal Dehydrogenase | 1 | 2009 | 13 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 2872 | 0.020 |
Why?
|
| Deoxyuracil Nucleotides | 1 | 2008 | 6 | 0.020 |
Why?
|
| RNA, Small Untranslated | 1 | 2008 | 20 | 0.020 |
Why?
|
| RNA Nucleotidyltransferases | 1 | 2008 | 32 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 6280 | 0.020 |
Why?
|
| Apolipoproteins E | 1 | 2009 | 188 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2008 | 53 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1078 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2009 | 334 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2011 | 518 | 0.020 |
Why?
|
| RNA Stability | 1 | 2008 | 75 | 0.020 |
Why?
|
| Nucleic Acid Conformation | 1 | 2008 | 180 | 0.020 |
Why?
|
| Calgranulin A | 1 | 2006 | 5 | 0.020 |
Why?
|
| S100 Proteins | 1 | 2006 | 40 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2006 | 141 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 667 | 0.020 |
Why?
|
| Receptors, Leukotriene | 1 | 2006 | 5 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 1236 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2006 | 286 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2008 | 450 | 0.020 |
Why?
|
| 3T3 Cells | 1 | 2005 | 121 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 2298 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 519 | 0.010 |
Why?
|
| Receptors, CXCR3 | 1 | 2004 | 23 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2004 | 47 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2004 | 38 | 0.010 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 36 | 0.010 |
Why?
|
| Adipocytes | 1 | 2005 | 173 | 0.010 |
Why?
|
| DNA Primers | 2 | 1996 | 609 | 0.010 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 33 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2003 | 75 | 0.010 |
Why?
|
| Free Radicals | 1 | 2003 | 35 | 0.010 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 37 | 0.010 |
Why?
|
| I-kappa B Kinase | 1 | 2003 | 57 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2003 | 141 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2003 | 125 | 0.010 |
Why?
|
| Lung Compliance | 1 | 2003 | 20 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 1395 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 66 | 0.010 |
Why?
|
| Body Composition | 1 | 2005 | 550 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2003 | 179 | 0.010 |
Why?
|
| Mucins | 1 | 2002 | 69 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2005 | 495 | 0.010 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 185 | 0.010 |
Why?
|
| Metabolic Syndrome | 1 | 2005 | 363 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2002 | 83 | 0.010 |
Why?
|
| Weight Loss | 1 | 2005 | 529 | 0.010 |
Why?
|
| Mast Cells | 1 | 2002 | 65 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2001 | 201 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2001 | 366 | 0.010 |
Why?
|
| Adolescent | 1 | 2019 | 20987 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 5297 | 0.010 |
Why?
|
| Mice, Inbred A | 1 | 2000 | 13 | 0.010 |
Why?
|
| Mice, Congenic | 1 | 2000 | 17 | 0.010 |
Why?
|
| Aerosols | 1 | 2000 | 60 | 0.010 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2000 | 60 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2002 | 464 | 0.010 |
Why?
|
| Basement Membrane | 1 | 2000 | 42 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 2000 | 123 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2000 | 129 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2005 | 1695 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2000 | 154 | 0.010 |
Why?
|
| Epithelium | 1 | 2000 | 343 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 2000 | 228 | 0.010 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1998 | 28 | 0.010 |
Why?
|
| Edema | 1 | 2000 | 139 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2000 | 244 | 0.010 |
Why?
|
| Diet | 1 | 2005 | 1119 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2002 | 692 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 1998 | 109 | 0.010 |
Why?
|
| DNA | 1 | 2003 | 1442 | 0.010 |
Why?
|
| Hemocyanins | 1 | 1996 | 24 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 1996 | 6 | 0.010 |
Why?
|
| Strongylida Infections | 1 | 1996 | 14 | 0.010 |
Why?
|
| Antigens, Ly | 1 | 1996 | 33 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1996 | 23 | 0.010 |
Why?
|
| Schistosomiasis mansoni | 1 | 1996 | 24 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 235 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1996 | 69 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 1996 | 116 | 0.010 |
Why?
|
| Granuloma | 1 | 1996 | 63 | 0.010 |
Why?
|
| Immunoglobulin D | 1 | 1994 | 6 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1993 | 40 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1993 | 152 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1994 | 376 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 989 | 0.010 |
Why?
|